Reewarm™ Gains CFDA Approval

MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") recently obtained the regulatory approval from China Food and Drug Administration ("CFDA") for its in-house developed Reewarm™ Peripheral Balloon Dilation Catheter ("Reewarm™"). Reewarm™ is designed to treat atherosclerosis-caused stenosis and occlusive disease in artery below groin, such as iliac artery, femoral artery, superficial femoral artery, popliteal artery, inferior genicular artery. It provides pre-expansion of the narrowed vascular lumen for future treatment.

Lower extremity arterial disease ("LEAD") is mainly caused by arterial atherosclerosis with narrowing or blocking of the arteries in the legs and feet, and would cause a range of severity of symptoms such as claudication, rest pain and even limb necrosis which may lead to lower limb necrosis and amputation, depending on the degree of narrowing at each vascular site. Such disease has severely impacted the life quality of Chinese senior citizens. According to statistics, the prevalence of peripheral artery diseases is expected to be 20 to 30 percent in a population aged over 65 and it is estimated that there are around 60 million people suffering from peripheral artery diseases in the world with an ever increasing incidence rate. However, medical devices to treat peripheral artery diseases are currently dominated by foreign companies. Zhenghua Miao, President of MicroPort® Endovascular, said: "As a domestically developed product, the market launch of Reewarm™ in China is expected to benefit Chinese patients with its high-quality and affordable price."
The Project "Research on a Minimal Invasive, High Efficiency Orthopedic Robotic System" Officially Launched in Shanghai

On June 28, the project "Research on a Minimal Invasive, High Efficiency Orthopedic Robotic System" was officially launched in Shanghai. The project was listed in the National Key Research & Development ("R&D") Plan, falling into the category of "Digital Diagnostic Equipment R&D." It is a four-year project co-developed by Suzhou MicroPort OrthoRecon Co., Ltd. ("MicroPort* OrthoRecon"), Shanghai Ninth People’s Hospital of Shanghai Jiaotong University, Peking University, Beijing Institute of Technology, Third Military Medical University, Fudan University, and Shanghai Medical Device Testing Institute.
MSC Launches Clinical Trial for CompassAnalyzer™ PSA

MicroPort Sorin CRM (Shanghai) Co., Ltd. ("MSC") recently hosted center initiation meetings of the pre-market clinical trial for its in-house developed CompassAnalyzer™ Pacing System Analyzer ("CompassAnalyzer™ PSA") in three hospitals of Shanghai. The clinical trial is the first pre-market multi-center clinical trial launched by MSC since the implementation of China’s Quality Control Regulations of Clinical Trials for Medical Devices from June 1, 2016. Up to date, several dozens of patients have been enrolled in the clinical trial.

The pacing system analyzer ("PSA") is external equipment needed in pacemaker implantation for physicians to evaluate electrical parameters of pacemaker leads. In recent years, with the phase out of the imported products that used to monopolize the market, the PSA market is almost a blank market with urgent demand for portable and easy-to-use PSAs.
MPSC New COO
Glendy Wang on Board

On July 2, MicroPort Scientific Corporation ("MPSC") (HK: 853) is pleased to announce that effective immediately Ms. Glendy Wang has joined MPSC as the Chief Operation Officer ("COO").

Ms. Wang has accumulated over 30 years of management and operation experience in top multinational medical device companies. Before joining MPSC, Ms. Wang served as Managing Director of Greater China of Smith & Nephew from 1997 to 2016. Ms. Wang also worked for Becton, Dickinson and Company ("BD") and Johnson & Johnson Taiwan.
**MicroPort® Orthopedics Hosts**

**US-Chinese Surgeons Academic Exchange Program**

MicroPort® Orthopedics recently hosted an academic exchange program for Chinese and US surgeons in Miami of US. During the one-week program, surgeons from Shanghai, Qingdao and Shenzhen closely worked with US experts and discussed together the cutting-edge technologies of joint replacement, centering around MicroPort® Orthopedics’ medial pivot knee systems.

The first part of the program was held in Miami Anatomical Research Center. Dr. Burke of Broward Medical Center explained the design rationale, clinical outcome and clinical experience of the medial pivot knee. He pointed out: "The medial compartment is more stable than the lateral compartment in knee flexion, and the mobility provided by the lateral compartment makes the femoral rotation in knee flexion." Designed based on such theories, the medial pivot knee guarantees stability, safety and high flexion compared to the traditional design of knee prostheses. Afterwards, in the cadaver lab, surgeons got hands-on experience with the surgical instrument of EVOLUTION® Medial-Pivot Knee System (“EVOLUTION™”) under the direction of Dr. Burke. With the combination of theory and practice, surgeons had better understanding in the medial pivot knee, and many of them spoke highly of the design of the knee system as well as the matching instrument.

The second and the third parts of the program were respectively held in Broward Medical Center and Crestwood Medical Center. In these two medical centers, nearly 800 joint replacement surgeries are performed annually. Surgical observations of total knee arthroplasty with medial pivot knee were specially arranged for Chinese surgeons. Dr. Janssen of Crestwood Medical Center and Dr. Burke perfectly utilized their surgical skills based on the design features of medial pivot knees, and had in-depth discussion with Chinese surgeons regarding incision approach, ostectomy, soft tissue balance, Intraoperative analgesia and perioperative management.
MicroPort® Orthopedics Holds the Second TKA Training Course in Hong Kong

On July 21, MicroPort® Orthopedics organized a two-day training course regarding total knee arthroplasty ("TKA") surgical technique in Hong Kong. Ten knee replacement experts from Zhejiang, Hebei, Jiangsu, Heilongjiang, Chongqing, Guangdong, Shandong and Hunan provinces attended the course to get a deeper understanding in the design rationale and surgical techniques of the medial-pivot knee.

The training course was chaired by Peter KY Chiu, a clinical professor and head of Ortho Recon of the Department of Orthopaedics & Traumatology of the University of Hong Kong, Queen Mary Hospital. As a renowned orthopedic expert, Professor Chiu is a life member of the Hong Kong Orthopaedic Association ("HKOA"). Professor Chiu has been engaged in providing medical education of knee surgical techniques to the Chinese mainland surgeons since 1998. From 2001, approximately 1,700 mainland orthopedic surgeons have come to Hong Kong for the surgical training.

This training course provided a thorough comprehension of the design rationale of the medial pivot knee as well as its advantages compared to traditional knee prostheses. Meanwhile, it is expected that the EVOLUTION™ surgical techniques the trainees learnt from the course would lay the foundation for them to carry out EVOLUTION™ surgeries in their local hospitals in the future. MicroPort® Orthopedics will continue to work closely with the Department of Orthopaedics & Traumatology of the University of Hong Kong to launch more TKA training courses, allowing more orthopedic surgeons to understand and use the medial pivot knee so as to benefit more patients.
MicroPort®
Attends BIOME Device China 2017

From July 21 to July 22, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort") attended the BIOME Device China 2017, during which Dr. Hongyan Jiang, Vice President of Research & Development Support and Shared Service, delivered a keynote speech on behalf of MicroPort. Hosted by Innovative Service Special Committee of China Association for Medical Devices Industry, the forum was themed on "Improving the Quality of Implantable/Interventional Devices and Shortening the Cycle of Product Research and Development (R&D)." Professionals from food and drug administrations, notified bodies, hospitals, and medical device companies were invited to give lectures on topics including the latest submission regulations and guidances at home and abroad, studies regarding the performance and safety of advanced biomedical devices, improving clinical trial protocol, accelerating clinical translation, and enhancing product quality and competitiveness by optimizing technology.

In recent years, MicroPort has achieved fruitful results in biomedical material field, especially in terms of import substitution. For instance, it develops implantation-grade polylactic acids degradable materials, and established independent implantation-grade textile platform, Precision Medical Tubing Extrusion and Injection Molding Center, and Special Material R&D and Processing Center. With its independent innovations, MicroPort hopes to break the monopoly of imported products, drive the industrialization of new biomedical materials and other related medical devices, and accelerate the promotion of clinical application, so as to help push forward the technology innovation in China's medical device industry especially high value-added medical consumable sectors including cardiovascular, orthopedic and artificial organ areas.
MicroPort® Attends 14th Cardiac Imaging & Cardiac Interventional Summit

From July 21 to July 23, Shanghai MicroPort Medical (Group) Co., Ltd. (“MicroPort®”) attended the 14th Cardiac Imaging & Cardiac Interventional Summit held in Beijing. Themed on "Collaboration, Innovation, Concentration, Intelligence," the congress focused on the latest advancement of cardiovascular imaging, precise treatment under the guidance of multimodal imaging, new technologies of coronary interventional treatment.
MicroPort® Attends OCC 2017

From May 25 to May 28, MicroPort® attended the 11th Oriental Congress of Cardiology ("OCC 2017") in Shanghai Expo Center and hosted a satellite meeting and a case contest.

On May 27, MicroPort® hosted a satellite meeting – "The Rhythm of MicroPort": the Latest Clinical Data of TARGET Series Studies," Professor Bo Xu of Fujai Hospital of Chinese Academy of Medical Sciences released the three-month Optical Computerized Tomography ("OCT") data from the TARGET All Comer trial for Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk"). TARGET All Comer is the first post-market randomized trial in 10 European countries for Firehawk®. The TARGET All Comer study started in December 2015 and completed its enrollment in October 2016. A total of 1,656 patients were enrolled, including pre-specified 50 in the OCT sub-study and 176 in a QCA sub-study (13-month follow-up). During the meeting, Professor Jinjie Dai of Shanghai Chest Hospital, Professor Huimin Liu of the Second Affiliated Hospital of Harbin Medical University, and Professor Kun Wang of Nanjing Drum Tower Hospital also shared some cases using Firehawk® to further demonstrate its excellent performance in clinical application, which was well received by experts in attendance.
MicroPort® EP Attends EUROPACE-CARDIOSTIM 2017

Shanghai MicroPort EP MedTech Co., Ltd. ("MicroPort® EP") recently attended EUROPACE-CARDIOSTIM 2017 hosted by European Heart Rhythm Association ("EHRA") in Vienna, Austria. More than 5,000 arrhythmia experts from all over the world participated in the congress. As an important cardiovascular subspeciality community of European Cardiac Rhythm Management, EHRA is committed to improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.

During the EUROPACE-CARDIOSTIM 2017, MicroPort® EP displayed products that have been launched in the market, including Columbus™ 3D EP Navigation System ("Columbus™"), OptimAblate™ RF Generator, OptimAblate™ Irrigation Pump, FireMagic® Cardiac RF Ablation Catheter, FireMagic® 3D Irrigated Ablation Catheter, and EasyFinder™ Electrophysiology Steerable Diagnostic Catheter, as well as innovative devices that are still under research and development, such as PathBuilder™ Fixed Curve/Steerable Introducer, Puncture Needle, and Rhythmwatch™ ECG Monitor, which attracted many experts to visit the booth and inquire for product information. In particular, the latest version of Columbus™ with added functions gained recognition from experts in Greece, Turkey and Dominica.
MicroPort® Endovascular
Attends the First Three Northeast Provinces
Aortic Disease Interventional Treatment Summit

On July 22, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") attended the First Three Northeast Provinces Aortic Disease Interventional Treatment Summit held in Changchun. Hosted by Chinese Association of Cardiovascular Surgeons and the First Hospital of Jilin University, the summit provided a platform for clinicians to exchange ideas on hot topics and difficult cases of aortic disease interventional treatment through typical case studies and special lectures.

Meanwhile, MicroPort® Endovascular introduced to the attendees the development history and future trend of its product portfolio, as well as the design, features and advantages of its existing products. MicroPort® Endovascular primarily focuses on R&D, and manufacturing support of the interventional medical devices, including AAA/TAAs stent graft systems, surgical stent graft system, aortic balloon dilation catheter and peripheral vascular stents/balloons. It will continue to strive for innovation and product diversification, to help promote the development of China's aortic surgical technique.
MicroPort® Lifesciences
Attends 2017 CEA Annual Meeting

From July 7 to July 8, Shanghai MicroPort Lifesciences Co., Ltd. ("MicroPort® Lifesciences") attended the 2017 Annual Meeting of Chinese Endocrinologist Association ("CEA") in Shanghai. More than 2,500 endocrinologists participated in the meeting and exchanged ideas regarding the clinical and academic advancement in endocrinology as well as the prevention and treatment of chronic diseases.

On July 7, Professor Shouyue Sun of Shanghai Ruijin Hospital of Shanghai Jiao Tong University gave a lecture on "Clinical Management of Gonadotropin-releasing Hormone ("GnRH") Pulsatile Therapy." According to Professor Sun, by the end of 2016, a total of 1,200 male patients and 200 female patients have used La Fenice® Hypophysseal Hormone Infusion Pump and have achieved great treatment effect. During his lecture, the attendees also had hot discussions with Professor Sun about the treatment of difficult IHH cases and clinical applications of GnRH pulsatile pump.
MicroPort® Lifesciences Hosts GnRH Pump Treatment Symposium

On July 24, MicroPort® Lifesciences hosted GnRH Pump Treatment Symposium in Guangzhou, Guangdong Province. Several local experts of endocrinology and metabolism, reproductive medicine, and sex medicine to exchange ideas on the latest advancement of clinical studies of Gonadotropin-releasing Hormone ("GnRH") Pulsatile pump in China. After lecture session, experts had hot discussions regarding the treatment of difficult IHH cases and the clinical application of GnRH pulsatile pump.
MicroPort® and Shanghai East Hospital Establish Translational Medicine Joint Research Center

On July 8, MicroPort® signed a strategic agreement with Shanghai East Hospital of Tongji University School of Medicine to jointly establish "Shanghai East Hospital – MicroPort® Translational Medicine Joint Research Center" and carry out comprehensive cooperation in cardiovascular diseases, cardiac failure, cardiac surgery, cerebrovascular diseases, and comprehensive diagnosis and treatment of tumors.

Shanghai East Hospital is a large-scale top hospital in China integrating medical treatment, academic education, scientific research, emergency service, and healthcare, covering 10 key subjects of Shanghai and China, and is specialized in cardiac failure treatment, cardiac surgery, cardiovascular diseases treatment, and comprehensive diagnosis and treatment of tumors. Based on the win-win principle, this strategic partnership between MicroPort® and Shanghai East Hospital leverages complementary strengths and resources of the two respected parties in the industry. By jointly establishing the translational medicine joint research center, MicroPort® and Shanghai East Hospital will focus on developing innovative medical devices, applying minimally invasive surgery technologies, cultivating medical talents, and launching academic workshops and exchange programs.
**MicroPort® EP Participates in a Free Clinic in Jiangxi**

On the occasion of celebrating the 96th anniversary of the Communist Party of China, a free clinic activity was held in Pingxiang of Jiangxi Province. Professor Dening Liao and Professor Yusheng Ren of Shanghai Changzheng Hospital and other experts from Shanghai top hospitals attended the event.

During this free clinic activity, Professor Dening Liao, with the assistance from Professor Gengqing Zhou of Shanghai General Hospital, used Columbus™ 3D EP Navigation System ("Columbus™"), in-house developed by MicroPort® EP, to do cardiac electrophysiological examination and radiofrequency ablation for eight arrhythmia patients. Such kind of operation demonstration allowed physicians in attendance to learn high-end operative techniques. According to the attendees, the procedure demonstrations largely enhanced the understanding of local medical staff in treating arrhythmias and indicated the development trend for similar procedures. Currently, an increasingly more physicians are using 3D mapping systems in radiofrequency ablation. In this free clinic activity, physicians provided high-quality medical service for local residents, which strongly enhanced the communications between medical staff of Shanghai and Jiangxi and promoted the development of Jiangxi healthcare industry.
Investor Newsletter
Issue 07 2017

For more information, please contact:

**Martin Sun**
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

**Leanne Li**
Board Secretary & VP of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com